Canonical and noncanonical wnt pathways: A comparison between endometrial cancer type I and atrophic endometrium in Brazil;Vias wnt canônica e não canônica: Uma comparação entre o câncer endometrial tipo I e endométrio atrófco no Brasil

Sao Paulo Medical Journal

Volumn 129, Issue 5, 2011, Pages 320-324

  Menezes, Marina de Pádua Nogueira ^a   Oshima, Celina Tizuko Fujiyama ^a   Filho, Levon Badiglian ^a   Gomes, Thiago Simão ^a   Barrezueta, Luis Fernando Mesias ^a   Stávale, João Norberto ^a   Gonçalves, Wagner José ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Endometrial neoplasms; Endometrium; postmenopause; Wnt proteins; Women

Indexed keywords

BETA CATENIN; FRIZZLED 1 PROTEIN; FRIZZLED 5 PROTEIN; FRIZZLED PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; WNT1 PROTEIN; WNT5A PROTEIN;

ARTICLE; BRAZIL; CANONICAL ANALYSIS; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENDOMETRIUM ATROPHY; ENDOMETRIUM CANCER; ENDOMETRIUM CANCER TYPE 1; ENDOMETRIUM CARCINOMA; FEMALE; FZD1 GENE; FZD5 GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR GENE; WNT GENE; WNT1 GENE; WNT5A GENE;

EID: 80755171394     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-31802011000500007     Document Type: Article

References (20)

1. Fukuchi T, Sakamoto M, Tsuda H, et al. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res. 1998;58(16):3526-8.
2. Schlosshauer PW, Pirog EC, Levine RL, Ellenson LH. Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma. Mod Pathol. 2000;13(10):1066-71.
3. Pijnenborg JM, Kisters N, van Engeland M, et al. APC, beta-catenin, and E-cadherin and the development of recurrent endometria carcinoma. Int J Gynecol Cancer. 2004;14(5):947-56.
4. Kariola R, Abdel-Rahman WM, Ollikainen M, et al. APC and beta-catenin protein expression patterns in HNPCC-related endometria and colorectal cancers. Fam Cancer. 2005;4(2):187-90.
5. Schlosshauer PW, Ellenson LH, Soslow RA. Beta-catenin and E-cadherin expression patterns in high-grade endometria carcinoma are associated with histological subtype. Mod Pathol. 2002;15(10):1032-7.
6. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009;16(1):8-13.
7. Wappenschmidt B, Wardelmann E, Gehrig A, et al. PTEN mutations do not cause nuclear beta-catenin accumulation in endometria carcinomas. Hum Pathol. 2004;35(10):1260-5.
8. Nei H, Saito T, Yamasaki H, et al. Nuclear localization of beta-catenin in normal and carcinogenic endometrium. Mol Carcinog. 1999;25(3):207-18.
9. Pecorelli S, Ngan HYN, Hacker NF. Staging Classifcations and Clinica Practice Guidelines for Gynaecological Cancers. Available from: http://www.fgo.org/fles/fgo-corp/docs/staging_booklet.pdf. Accessed in 2011 (May 12).
10. Hou X, Tan Y Li M, Dey SK, Das SK. Canonical Wnt signaling is critical to estrogen-mediated uterine growth. Mol Endocrinol. 2004;18(12)3035-3049.
11. Kouzmenko AP Takeyama K, Ito S, et al. Wnt/beta-catenin and estrogen signaling converge in vivo. J Biol Chem. 2004;279(39):40255-8.
12. Zhang Q, Shen Q, Celestino J, et al. Enhanced estrogen-induced proliferation in obese rat endometrium. Am J Obstet Gynecol. 2009;200(2):186.e1-8.
13. Ishitani T, Kishida S, Hyodo-Miura J, et al. The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Mol Cell Biol. 2003;23(1):131-9.
14. Topol L, Jiang X, Choi H, et al. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol. 2003;162(5):899-908.
15. Singleton DW, Feng Y, Yang J, et al. Gene expression profling reveals novel regulation by bisphenol-A in estrogen receptor-alpha-positive human cells. Environ Res. 2006;100(1):86-92.
16. Jönsson M, Dejmek J, Bendahl PO, Andersson T. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res. 2002;62(2):409-16.
17. Fernandez-Cobo M, Zammarchi F, Mandeli J, Holland JF, Pogo BG. Expression of Wnt5A and Wnt10B in non-immortalized breast cancer cells. Oncol Rep. 2007;17(4):903-7.
18. Benhaj K, Akcali KC, Ozturk M. Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol Rep. 2006;15(3):701-7.
19. Badiglian Filho L, Oshima CT, De Oliveira Lima F, et al. Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep. 2009;21(2):313-20.
20. Bui TD, Zhang L, Rees MC, Bicknell R, Harris AL. Expression and hormone regulation of Wnt2, 3, 4, 5a, 7a, 7b and 10b in normal human endometrium and endometrial carcinoma. Br J Cancer. 1997;75(8):1131-6.